SUNNYVALE, Calif. (BUSINESS WIRE) June 13, 2006 Intraop Medical Corporation (OTCBB: IOPM) has received encouraging reports of significant local control and survival benefits for patients with advanced head and neck cancer who received intraoperative electron radiation therapy (IOERT) as part of their treatment.

The studies were conducted at The Arthur James Cancer Center at The Ohio State University in Columbus, Ohio, one of seven U.S. centers currently equipped with a Mobetron®. These results are significant for the company because Intraop is the developer of the Mobetron, the world's first and only mobile electron-beam system designed exclusively for this kind of treatment.

One study involved patients with hypopharyngeal cancer. This uncommon cancer has one of the worst prognoses for tumors of the upper aerodigestive tract, with five-year survival rates ranging from 19% to 31% when using only surgery, conventional radiation and chemotherapy. In the current study that added IOERT, the five-year survival rate was 56%, and more than 90% of the patients achieved local control of their disease.

The second study included locally advanced tumors of the oral cavity and oropharynx. Standard treatment regimens for these tumors produce four-year survival rates of less than 38%. When IOERT was added, the survival rate was 72%, and overall local control of the disease was 93%.

"Head and neck cancers are very difficult to treat because so many vital structures in this region of the body need to be preserved to provide good quality of life for the patient. These new studies are further evidence that IOERT provides unique benefits to patients with locally advanced diseases," said Dr. Donald Goer, President and CEO of Intraop Medical. "IOERT delivers the equivalent of several weeks of conventional radiation in only a few minutes at the time of the surgical procedure to remove the tumor. Normal, healthy tissues are moved aside or protected, thus reducing the risk of damaging nearby vital structures."

Dr. Goer concluded: "We continue to be encouraged by the ongoing reporting of clinical results in peer-reviewed journals. Additionally, positive results using IOERT with not only head and neck but a variety of cancers, including breast, gastrointestinal, genitourinary, gynecological, thoracic, orthopedic and pediatric, have led to increased interest in the Mobetron on the part of radiation and surgical oncology specialists."

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.